Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3798-3807

  Hirsch, Fred R ^a   Varella Garcia, Marileila ^a   Bunn Jr , Paul A ^a   Di Maria, Michael V ^a   Veve, Robert ^a   Bremnes, Roy M ^a   Barón, Anna E ^a   Zeng, Chan ^a   Franklin, Wilbur A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CHROMOSOME 7; CONTROLLED STUDY; DISOMY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TRISOMY; AGED; FEMALE; GENE DOSAGE; GENETICS; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PLOIDY; PROTO ONCOGENE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE DOSAGE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLOIDIES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0142119289     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.069     Document Type: Article

References (38)

1. Maxwell PD: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
2. Jemal A, Thomas A, Murray T, et al: Cancer statistics 2002. CA Cancer J Clin 52:23-47, 2002
3. Yarden Y, Sliwkowski M: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
4. Stoscheck CM, King LE: The role of epidermal growth factor in carcinogenesis. Cancer Res 46:1030-1037, 1986
5. Sobol RE, Astarita RW, Hofeditz C, et al: Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 79:403-405, 1987
6. Berger MS, Gullick WJ, Greenfield C, et al: Epidermal growth factor receptors in lung tumours. J Pathol 152:297-307, 1987
7. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: Targeting epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
8. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancer and adjacent benign lung. Cancer Res 53:2379-2385, 1993
9. Kurie JM, Sjon HJC, Lee JS, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2:1787-1793, 1996
10. Piyathilake CJ, Frost AR, Manne U, et al: Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8:734-744, 2002
11. Lonardo F, Dragnev KH, Freemantle SJ, et al: Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 8:54-60, 2002
12. Franklin WA, Veve R, Hirsch FR, et al: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29:3-14, 2002 (suppl 4)
13. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER2/neu in non-small cell lung cancer by immunohistochemistry and fluorescence in-situ hybridization (FISH) techniques. Br J Cancer 86:1449-1456, 2002
14. Volm M, Rittgen W, Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663-669, 1998
15. Phsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603-607, 2000
16. Cox G, Jones JL, O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6:2349-2355, 2000
17. Rusch V, Klimstra D, Venkatraman E, et al: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in respectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522, 1997
18. Pfeiffer P, Clausen PP, Andersen K, et al: Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: An immunohistochemical study on cryosections. Br J Cancer 74:86-91, 1996
19. Fontanini G, De Laurentis M, Vignati S, et al: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249, 1998
20. Greatens TM, Niehans GA, Rubins JB, et al: Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157:1093-1097, 1998
21. D'Amico TA, Massey M, Herndon JE II, et al: A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999
22. Pastorino U, Andreola S, Tagliabue E, et al: Immunocytochemical markers in stage I lung cancers: Relevance to prognosis. J Clin Oncol 15:2858-2865, 1997
23. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001
24. Wang Y, Minoshima S, Shimizu N: Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved FISH technique. Jpn J Hum Genet 38:399-406, 1993
25. Reissmann PT, Koga H, Figlin RA, et al: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. J Cancer Res Clin Oncol 125:61-70, 1999
26. Reinmuth N, Brandt B, Kunze WP, et al: Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 16:991-996, 2000
27. Travis WD, Colby TV, Corrin B, et al: Histologic Typing of Tumours of Lung and Pleura: World Health Organization International Classification of Tumors (ed 3). New York, NY, Springer Verlag, 1999
28. Ekstrand AJ, Sugawa N, James CD, et al: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 89:4309-4313, 1992
29. Moscatello DK, Holgado-Madruga M, Godwin AK, et al: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539, 1995
30. Wikstrand CJ, Hale LP, Batra SK, et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148, 1995
31. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al: Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220, 1993
32. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
33. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens IDEAL2. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
34. Perez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients with advanced EGFR expressing non-small cell lung cancer. Proc Am Soc Clin Oncol 20:310a, 2001 (abstr 1235)
35. Herbst R, Natale R, Giaccone G, et al: ZD1839 improves disease-related symptoms and quality of life of patients with locally advanced or metastatic non-small cell lung cancer in two randomized, double-blind studies (IDEAL 1 and IDEAL 2). Chest 122:166S, 2002 (abstr)
36. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182, 1987
37. Pauletti G, Dandekar S, Rong HM, et al: Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
38. Ruckdeschel JC, Simon G, Antonia S, et al: ZD1839 (Iressa) as a single agent for the treatment of metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 21:318a, 2002 (abstr 1269)